Company · Healthtech & Bio

Biointaxis

biointaxis.com ↗ ·Badalona ·Seed

Biointaxis is a Barcelona-based biotech spin-off from the Germans Trias i Pujol Research Institute (IGTP), founded in 2018, developing AAV-based gene therapy (BTX-101/FRATAXAV) to treat Friedreich's ataxia, a rare inherited neurodegenerative disease with no current treatment. The company is advancing through pre-clinical proof-of-concept toward Phase I/II clinical trials, with plans to license the therapy to pharmaceutical partners.

Founded

2018

Founders

News

Rounds

Investors

SectorsBiotechnology, Gene Therapy, Rare Diseases, Healthtech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 31 Jul 2026

Founders

Antoni Matilla Dueñas

CEO & Co-Founder

Ivelisse Sánchez

CSO & Co-Founder

Jaime Melendo

Board Member & Co-Founder

—

Global models 5

AskBio

United States · www.askbio.com ↗

AAV gene therapy platform company that developed rare-disease gene therapies from academic research and was acquired by a large pharma (Bayer) for up to $4B, mirroring Biointaxis's academic-spinout-to-pharma-licensing model.

$235MComparable

Generation Bio

United States · www.generationbio.com ↗

Gene therapy biotech developing curative treatments for rare genetic diseases, raised largely via VC before going public.

$227MComparable

Passage Bio

United States · www.passagebio.com ↗

University of Pennsylvania academic spin-out developing AAV gene therapies for rare, monogenic CNS/neurodegenerative disorders, closely matching Biointaxis's academic-origin, rare-neuro-disease AAV model.

$226MComparable

Taysha Gene Therapies

United States · www.tayshagtx.com ↗

UT Southwestern academic spin-out developing AAV gene therapies for severe monogenic CNS diseases, the same academic-spinout AAV rare-disease model as Biointaxis.

$200MComparable

Voyager Therapeutics

United States · www.voyagertherapeutics.com ↗

AAV gene therapy company targeting severe neurological diseases via viral vector delivery, directly comparable to Biointaxis's gene therapy approach for Friedreich's ataxia.

$105MComparable

Investors 2

Funding rounds 1

Other · €2.17M

Biointaxis, a spin-off of the Germans Trias i Pujol Research Institute developing a gene therapy for Friedreich's ataxia that reaches both t…

2024-10-23

News & media

No coverage on record yet.